Ratio | Cetuximab 24Â h, group A | Cetuximab 24Â h, group B | Cetuximab 48Â h, group A | Cetuximab 48Â h, group B | Cetuximab 72Â h, group A | Cetuximab 72Â h, group B | ||||
 Tumour/blood | 0.20 ± 0.03 | 0.26 ± 0.01 | 0.24 ± 0.06 | 0.24 ± 0.01 | 0.54 ± 0.09 | 0.77 ± 0.15 | ||||
 Tumour/liver | 0.49 ± 0.08 | 0.76 ± 0.15 | 0.72 ± 0.25 | 0.63 ± 0.09 | 1.31 ± 0.01 | 1.34 ± 0.20 | ||||
 Tumour/muscle | 2.12 ± 0.38 | 3.41 ± 0.37 | 2.32 ± 0.58 | 2.73 ± 1.17 | 4.54 ± 0.59 | 5.42 ± 0.86 | ||||
 |  |  | Trastuzumab 48 h group A | Trastuzumab 48 h group B | Trastuzumab 72 h group A | Trastuzumab 72 h group B | ||||
 Tumour/blood |  |  |  |  |  |  | 0.57 ± 0.04 | 0.95 ± 0.22 | 0.63 ± 0.14 | 0.73 ± 0.17 |
 Tumour/liver |  |  |  |  |  |  | 1.64 ± 0.52 | 2.50 ± 0.71 | 1.84 ± 0.38 | 1.63 ± 0.14 |
 Tumour/muscle |  |  |  |  |  |  | 2.18 ± 0.48 | 4.12 ± 0.51 | 2.37 ± 0.49 | 3.17 ± 0.56 |